
Cellmid Limited


Maria Halasz
Chief Executive Officer

3 November 2010

CELLMID



CELLMID



- By indication
- Non-exclusive
- Protein or genomics
- CK3000 (screen)
- CAN105 (vet)
- CAMI103 (AMI)
- CMS101 (Multiple)
- CGRO106 (hair growth)

Investment highlights

- **Multiple revenue source**

- Cancer diagnostic licenses
- Cancer diagnostic in-house products
- Antibody therapeutics
- Midkine protein therapeutics
- Cosmeceuticals

- **Reduced risk**

- Diagnostic and therapeutic products around the same target
- Multiple partnership opportunities
- Extensively validated technology (clear MOA)
- Strong scientific backing (over 250 publications)

- **High value therapeutic antibody portfolio**

- Disease indications with major markets and unmet medical needs
- Meaningful preclinical validation (target conserved)

- **Powerful patent position**

- Exclusive owner of novel target (midkine) for diagnosis and treatment of cancer, autoimmune diseases and cosmeceuticals

Achievements since 2009 AGM

- Dec 2009 Raised \$3.63M in a private placement
- Feb 2010 Completed first antibody production
- March 2010 Signed collaboration for heart attack program with Pharmahungary
- April 2010 Signed research agreement with Kumamoto University for CK3000 cancer screening program
- May 2010 Signed diagnostic license with Pacific Edge
- Aug 2010 Completed preclinical trials on MS model
- September 2010 Signed up to \$8.5M convertible note facility over 3 years
- October 2010 Launched lifestyle subsidiary, Advangen
- November 2010 Completed and launched MK ELISA

Cellmid's MK ELISA

- Validation of the MK ELISA is complete
- Cellmid's first product (35 kits in inventory)




MK ELISA: Performance

- Limit of detection is 8pg/ml; well within the range of healthy serum MK levels of 0-300pg/ml
- Precise measurement with inter-assay CV <25%
- Accurate with a recovery range of between 75% and 125%
- Highly specific with no cross-reactivity to pleiotrophin or other serum components



Programs for 2011



Upcoming milestones

- Launch the Advangen range of hair loss prevention products – 4Q2010
- Complete veterinary cancer diagnostic trials - 2Q2011
- Complete stages 3-4 of AMI pre-clinical trials in preparation for IND – 3Q2011
 - Efficacy trials on single dose
 - Whole body retention studies
- Complete stage 1 of CK3000 clinical trials (cancer screening) - 3Q2011
 - Completion of testing of the first 500 healthy and patient blood samples
- Complete pre-clinical studies for midkine hair growth product - 4Q2011
 - Long term safety
 - 28 day efficacy studies
- Cancer diagnostic out-licensing - ongoing

Board and management

- David King (Chairman)
- Maria Halasz (CEO and Managing Director)
- Robin Beaumont (Non-executive Director)
- Koichiro Koike (Non-executive Director)
- Darren Jones (Head of Product Development)
- Nicholas Falzon (Company Secretary)



Thank you

Maria Halasz

Chief Executive Officer

E: halasz@cellmid.com.au

T: +61 2 9299 0311

www.cellmid.com.au